Really striking graphic shared by Gilead's Kesha O'Reilly showing how much access different parts of the country have to clinical trials. The darker blocks have better access and lighter areas have worse access. #REpharmaUSA

Boehringer Ingelheim's Paul Petraro and Sanjay Unni are discussing the concept of "holistic real-world evidence". The be-all and end-all of data collection is no longer the clinical trial, Petraro says. The data lifecycle is much longer and has to be considered in full from the start. #REpharmaUSA

My question is “waiting for review”. Several others have been approved since I sent it. Disappointing. #REpharmaUSA

Now @boehringerglobal.bsky.social's Brian Hilberdink is on stage for an interview. #REpharmaUSA

He's talking about BI's upcoming entry into the obesity market. There are >100M potential patients but only about 3M getting treated with current drugs. So there's plenty of room in the market for more.

At #REpharmaUSA today in Philadelphia. Great crowd and energy. Hoping to post some updates and insights here throughout the next couple days.